Description

Retatrutide & 5-Amino-1MQ — Mechanistic Rationale and Protocol Considerations

The combination of Retatrutide and 5-Amino-1MQ is frequently explored in research settings focused on metabolic optimisation, adiposity reduction, and energy regulation. This stack is designed to simultaneously target appetite signalling, glucose metabolism, and intracellular energy utilisation pathways.

Click to access Protocols-3.pdf

Mechanistic Complementarity

• Retatrutide: A multi-receptor agonist targeting pathways associated with GLP-1 receptor agonism, glucagon, and GIP signalling. Research suggests Retatrutide may significantly influence appetite suppression, glucose regulation, and energy expenditure.
• 5-Amino-1MQ: Functions as an inhibitor of Nicotinamide N-methyltransferase, an enzyme involved in metabolic efficiency, adiposity regulation, and NAD⁺ utilisation. NNMT inhibition may support enhanced fat oxidation and improved metabolic flexibility.

Strategic Sequencing

• Retatrutide is commonly introduced first to establish appetite regulation and improve metabolic control.
• 5-Amino-1MQ is then incorporated to further enhance intracellular metabolic activity and support substrate utilisation.
• This approach is intended to optimize caloric regulation while simultaneously improving energy expenditure and mitochondrial efficiency.

Dosing and Administration Framework

• Retatrutide:
  • Commonly initiated at 1–2 mg weekly
  • Gradually escalated toward 4–8 mg weekly depending on protocol objectives and tolerability
• 5-Amino-1MQ:
  • Commonly administered at 50–100 mg daily
  • Frequently divided into morning and afternoon doses
  • Morning fasted administration is commonly utilised in metabolic-focused protocols
• Timing:
  • Retatrutide administered once weekly on a consistent schedule
  • 5-Amino-1MQ administered daily to maintain metabolic pathway engagement

Functional Synergy

• Retatrutide primarily influences appetite control, satiety signaling, and systemic glucose handling.
• 5-Amino-1MQ enhances intracellular metabolic efficiency and may promote increased fat utilisation through modulation of NNMT-related pathways.
• Together, the combination is intended to support reductions in fat mass while improving metabolic flexibility and energy regulation.

Example Research Approach

• Cycle Duration: ~12–16 weeks
  • Early phase focused on gradual Retatrutide titration and metabolic adaptation
  • Continuous 5-Amino-1MQ administration maintained throughout the protocol
• Maintenance / Optimisation Phase:
  • Retatrutide dosage adjusted based on appetite response and metabolic markers
  • 5-Amino-1MQ maintained to support ongoing metabolic efficiency and substrate utilisation

This combination represents a dual-pathway metabolic optimisation strategy targeting appetite regulation, glucose metabolism, intracellular energy pathways, and adiposity reduction concurrently.